Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free TRLS Stock Alerts

Trellus Health (TRLS) Competitors

GBX 0.12 0.00 (0.00%)
As of 07/10/2026
Compare

TRLS vs. IQAI, DVRG, SENS, EMIS, and CRW

Should you buy Trellus Health stock or one of its competitors? MarketBeat compares Trellus Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trellus Health include IQ-AI (IQAI), DeepVerge (DVRG), Sensyne Health (SENS), EMIS Group (EMIS), and Craneware (CRW). These companies are all part of the "health information services" industry.

How does Trellus Health compare to IQ-AI?

IQ-AI (LON:IQAI) and Trellus Health (LON:TRLS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

1.6% of Trellus Health shares are owned by institutional investors. 66.0% of IQ-AI shares are owned by insiders. Comparatively, 9.6% of Trellus Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

IQ-AI has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market. Comparatively, Trellus Health has a beta of 2.509, meaning that its stock price is 151% more volatile than the broader market.

In the previous week, IQ-AI's average media sentiment score of 0.00 equaled Trellus Health'saverage media sentiment score.

Company Overall Sentiment
IQ-AI Neutral
Trellus Health Neutral

IQ-AI has higher revenue and earnings than Trellus Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IQ-AI£538.19K3.30N/AN/AN/A
Trellus Health£359K1.44-£7.98M-£5.00N/A

IQ-AI has a net margin of -77.52% compared to Trellus Health's net margin of -6,826.32%. Trellus Health's return on equity of -49.78% beat IQ-AI's return on equity.

Company Net Margins Return on Equity Return on Assets
IQ-AI-77.52% -140.75% -22.03%
Trellus Health -6,826.32%-49.78%-22.76%

Summary

IQ-AI beats Trellus Health on 5 of the 9 factors compared between the two stocks.

How does Trellus Health compare to DeepVerge?

Trellus Health (LON:TRLS) and DeepVerge (LON:DVRG) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

1.6% of Trellus Health shares are held by institutional investors. Comparatively, 4.2% of DeepVerge shares are held by institutional investors. 9.6% of Trellus Health shares are held by insiders. Comparatively, 9.5% of DeepVerge shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Trellus Health's average media sentiment score of 0.00 equaled DeepVerge'saverage media sentiment score.

Company Overall Sentiment
Trellus Health Neutral
DeepVerge Neutral

DeepVerge has higher revenue and earnings than Trellus Health. Trellus Health is trading at a lower price-to-earnings ratio than DeepVerge, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trellus Health£359K1.44-£7.98M-£5.00N/A
DeepVerge£12.41M0.00-£2.46M-£0.01N/A

DeepVerge has a net margin of -19.81% compared to Trellus Health's net margin of -6,826.32%. DeepVerge's return on equity of -10.27% beat Trellus Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Trellus Health-6,826.32% -49.78% -22.76%
DeepVerge -19.81%-10.27%-5.56%

Trellus Health has a beta of 2.509, meaning that its share price is 151% more volatile than the broader market. Comparatively, DeepVerge has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Summary

DeepVerge beats Trellus Health on 7 of the 10 factors compared between the two stocks.

How does Trellus Health compare to Sensyne Health?

Sensyne Health (LON:SENS) and Trellus Health (LON:TRLS) are both small-cap health information services industry companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

In the previous week, Sensyne Health's average media sentiment score of 0.00 equaled Trellus Health'saverage media sentiment score.

Company Overall Sentiment
Sensyne Health Neutral
Trellus Health Neutral

Sensyne Health has a net margin of 0.00% compared to Trellus Health's net margin of -6,826.32%. Sensyne Health's return on equity of 0.00% beat Trellus Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Sensyne HealthN/A N/A N/A
Trellus Health -6,826.32%-49.78%-22.76%

1.6% of Trellus Health shares are owned by institutional investors. 9.6% of Trellus Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Sensyne Health has higher revenue and earnings than Trellus Health. Trellus Health is trading at a lower price-to-earnings ratio than Sensyne Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sensyne Health£7.81M0.00N/A-£22.10N/A
Trellus Health£359K1.44-£7.98M-£5.00N/A

Summary

Sensyne Health beats Trellus Health on 5 of the 8 factors compared between the two stocks.

How does Trellus Health compare to EMIS Group?

EMIS Group (LON:EMIS) and Trellus Health (LON:TRLS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

In the previous week, EMIS Group's average media sentiment score of 0.00 equaled Trellus Health'saverage media sentiment score.

Company Overall Sentiment
EMIS Group Neutral
Trellus Health Neutral

EMIS Group has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market. Comparatively, Trellus Health has a beta of 2.509, suggesting that its share price is 151% more volatile than the broader market.

EMIS Group has higher revenue and earnings than Trellus Health. Trellus Health is trading at a lower price-to-earnings ratio than EMIS Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EMIS Group£176.86M0.00£30.48M£0.47N/A
Trellus Health£359K1.44-£7.98M-£5.00N/A

105.6% of EMIS Group shares are held by institutional investors. Comparatively, 1.6% of Trellus Health shares are held by institutional investors. 3.6% of EMIS Group shares are held by company insiders. Comparatively, 9.6% of Trellus Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

EMIS Group has a net margin of 17.23% compared to Trellus Health's net margin of -6,826.32%. EMIS Group's return on equity of 23.17% beat Trellus Health's return on equity.

Company Net Margins Return on Equity Return on Assets
EMIS Group17.23% 23.17% 7.99%
Trellus Health -6,826.32%-49.78%-22.76%

Summary

EMIS Group beats Trellus Health on 8 of the 10 factors compared between the two stocks.

How does Trellus Health compare to Craneware?

Trellus Health (LON:TRLS) and Craneware (LON:CRW) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

In the previous week, Craneware had 2 more articles in the media than Trellus Health. MarketBeat recorded 2 mentions for Craneware and 0 mentions for Trellus Health. Craneware's average media sentiment score of 1.22 beat Trellus Health's score of 0.00 indicating that Craneware is being referred to more favorably in the news media.

Company Overall Sentiment
Trellus Health Neutral
Craneware Positive

Craneware has higher revenue and earnings than Trellus Health. Trellus Health is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trellus Health£359K1.44-£7.98M-£5.00N/A
Craneware£211.33M1.87£14.27M£62.9018.35

Craneware has a consensus price target of GBX 2,222.75, suggesting a potential upside of 92.53%. Given Craneware's stronger consensus rating and higher probable upside, analysts plainly believe Craneware is more favorable than Trellus Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trellus Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Craneware
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Trellus Health has a beta of 2.509, indicating that its share price is 151% more volatile than the broader market. Comparatively, Craneware has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

Craneware has a net margin of 10.63% compared to Trellus Health's net margin of -6,826.32%. Craneware's return on equity of 6.65% beat Trellus Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Trellus Health-6,826.32% -49.78% -22.76%
Craneware 10.63%6.65%2.28%

1.6% of Trellus Health shares are held by institutional investors. Comparatively, 36.5% of Craneware shares are held by institutional investors. 9.6% of Trellus Health shares are held by company insiders. Comparatively, 10.3% of Craneware shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Craneware beats Trellus Health on 15 of the 16 factors compared between the two stocks.

Get Trellus Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRLS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRLS vs. The Competition

Export
MetricTrellus HealthHealth Information Services IndustryMedical SectorLON Exchange
Market Cap£516K£309.80M£7.05B£2.76B
Dividend YieldN/A6.07%2.68%6.16%
P/E Ratio-0.02302.2327.11368.11
Price / Sales1.44138.34589.9684,635.11
Price / Cash0.7647.1429.2227.87
Price / Book0.017.5610.747.47
Net Income-£7.98M-£22.78M£3.58B£5.89B
7 Day PerformanceN/A-0.81%-2.11%-0.36%
1 Month PerformanceN/A-0.04%3.27%-1.13%
1 Year Performance-81.54%-9.08%26.31%61.65%

Trellus Health Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRLS
Trellus Health
N/AGBX 0.12
flat		N/AN/A£516K£359KN/A31
IQAI
IQ-AI
N/AGBX 0.80
flat		N/A+0.0%£1.77M£538.19KN/A6
DVRG
DeepVerge
N/AN/AN/AN/A£1.14M£12.41MN/A73
SENS
Sensyne Health
N/AN/AN/AN/A£583K£7.81MN/A70
EMIS
EMIS Group
N/AN/AN/AN/A£1.23B£176.86M4,085.111,560

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:TRLS) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your money is changing
Porter Stansberry - who warned readers about Fannie Mae in 2006, called gold in 2008, and predicted COVID-era ...
Porter & Company | Sponsoredtc pixel
The $5 company SpaceX can’t survive without
The investors who got rich on AI didn't all buy Nvidia. Some bought ASML, the company that makes the machines ...
Traders Agency | Sponsoredtc pixel
Trump Set to Unleash 219-Year-Old “Super Weapon” on U.S. Soil
Four-time U.S. Presidential advisor Jim Rickards is warning of a political move he calls 'The Trump Supremacy'...
Paradigm Press | Sponsoredtc pixel
60 years. Zero competitors.
One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...
Behind the Markets | Sponsoredtc pixel